Loading…
← CockpitCompetitor Analysis › 086900.KS Medy-Tox Inc.Open in the cockpit ↗

Medy-Tox Inc.086900.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology
Momentum strong 61
Mkt cap
$350M
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$1.19M
20-day average traded
Fwd P/E
18.1×
forward earnings
ROIC−WACC
-1.7 pp
WACC 5.4%
Hurdle
-7 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · KRW₩68,400
1D-2.8%
1W-0.9%
1M-2.0%
3M-11.1%
6M-35.6%
YTD-43.4%
1Y-42.5%
ATR %4.5%
52w lowhigh51.5% off high

What Medy-Tox does

Employees: 753

Medy-Tox at a glance

Size Medy-Tox (086900.KS) is a South Korea Health Care company (Biotechnology) with a market value of $350M, the 438th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩68,400 on 18 Nov 2026.

Performance Over six months the shares fell 35.6%, against -31.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 3.1% over the last twelve months (peer median +7.2%); the operating margin is 9.6% (peer median -18.5%).

Valuation It trades at 18.1× forward earnings against a peer median of 16.2× (2nd most expensive of 4).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.7 points below its cost of capital (5.4% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 68086900.KS 67
Six months, rebased to 100: Medy-Tox against the median of its 20 peers (local-currency closes).

Medy-Tox financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩249B₩247B₩229B₩221B₩195B
Revenue growth—+8%+3%+13%—
Gross profit₩152B₩137B₩132B₩128B₩124B
EBITDA₩44.2B₩36.6B₩40.3B₩32.7B₩61.8B
Net income₩19.5B₩16.6B₩17.0B₩9.76B₩37.0B
Free cash flow₩47.7B₩45.8B₩24.5B₩2.98B₩14.2B
Capital expenditure₩28.4B₩34.2B₩18.7B₩37.5B₩25.1B
Total debt₩124B₩76.6B₩87.2B₩82.8B₩121B

Quarterly statements and history in the cockpit →

Medy-Tox competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-25%0%+25%CRMDLYEL358570CTNMLRMR47606038803003812105CCCCPRTC6945ALEC7630300966PNVPROK688687086900.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Medy-Tox is the large dot.

Fundamentals: revenue growth against valuation

+5%+10%25×50×75×3880PNV688687086900.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Medy-Tox is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%+600%0%250%500%750%476060PNV688687086900.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Medy-Tox is the large dot.

Medy-Tox competitors and peer comparison

How Medy-Tox compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Medy-Tox against its 20 peers (data as of 18 Nov 2026)
Measure086900.KSPeer medianRank in peer set
1-month return-2.0%-5.7%9th highest of 20
6-month return-35.6%-31.1%8th lowest of 20
Distance from 52-week high-51.5%-49.8%10th lowest of 20
Revenue growth (TTM)+3.1%+7.2%5th lowest of 16
Operating margin9.6%-18.5%5th highest of 17
Forward P/E18.1×16.2×2nd most expensive of 4
Growth the price implies (Req g, 7 yrs)4.7%36.6%2nd least demanding of 4
Growth delivered (Del g)+11.9%+37.6%2nd lowest of 4
Hurdle (Req g minus delivered)-7.2 pp+14.3 pp2nd least demanding of 4
ROIC minus cost of capital-1.7 pp-9.4 pp4th highest of 16
EV / EBITDA12.4×13.2×4th cheapest of 7
Net debt / EBITDA1.7×-2.9×most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%18.1×4.7%+11.9%
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
CorMedix CRMDUnited States$358M-43%+92%39%n/an/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%n/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%n/an/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%n/a0.6%+725.2%
Medtide 3880.HKHong Kong$331M-17%+14%36%10.5×n/an/a
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%n/an/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%n/an/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%n/an/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%n/an/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
Alector ALECUnited States$383M+21%+151%25%n/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%n/an/an/a
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%n/an/an/a
Polynovo PNV.AXAustralia$388M-34%+13%5%84.0×51.9%+37.6%
ProKidney PROKUnited States$314M-38%+4%-24,830%n/an/an/a
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%16.2×36.6%+8.9%
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%n/an/an/a

Questions

Which companies are Medy-Tox's closest peers?
The cockpit's peer set: Aspen Neuroscience (ASPE), CorMedix (CRMD), Lyell Immunopharma (LYEL), GI Innovation (358570.KS), Contineum Therapeutics (CTNM), Larimar Therapeutics (LRMR), Onconic Therapeutics (476060.KS), Medtide (3880.HK).
Is Medy-Tox expensive compared with its peers?
On forward p/e it trades at 18.1× against a peer median of 16.2×, 2nd most expensive of 4 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Medy-Tox stock performed?
Over six months to 18 Nov 2026 the shares returned -35.6% against -31.1% for the median peer; over one year -42.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.